These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 22297733

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM.
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [Abstract] [Full Text] [Related]

  • 3. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M, Quinlivan R, Tirupathi S, Blackwood B.
    Cochrane Database Syst Rev; 2017 Jan 24; 1(1):CD010899. PubMed ID: 28117876
    [Abstract] [Full Text] [Related]

  • 4. Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study.
    Misof BM, Roschger P, McMillan HJ, Ma J, Klaushofer K, Rauch F, Ward LM.
    J Bone Miner Res; 2016 May 24; 31(5):1060-9. PubMed ID: 26615086
    [Abstract] [Full Text] [Related]

  • 5. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C, Wong BL, Hornung L, Khoury JC, Rybalsky I, Shellenbarger KC, Rutter MM.
    Neuromuscul Disord; 2020 Jul 24; 30(7):599-610. PubMed ID: 32680651
    [Abstract] [Full Text] [Related]

  • 6. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, Ahmed SF, Wong SC, UK NorthStar Clinical Network.
    JAMA Neurol; 2019 Jun 01; 76(6):701-709. PubMed ID: 30855644
    [Abstract] [Full Text] [Related]

  • 7. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan 01; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 8. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A, Schaeffer EK, Reilly CW.
    J Pediatr Orthop; 2018 Jul 01; 38(6):320-324. PubMed ID: 27328118
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM.
    Neuromuscul Disord; 2016 Nov 01; 26(11):760-767. PubMed ID: 27614576
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vertebral fractures and increased sensitivity to corticosteroids in a child with ulcerative colitis: successful use of pamidronate.
    Lucarelli S, Borrelli O, Paganelli M, Capocaccia P, Frediani T, Ferri F, Cucchiara S.
    J Pediatr Gastroenterol Nutr; 2006 Oct 01; 43(4):533-5. PubMed ID: 17033531
    [No Abstract] [Full Text] [Related]

  • 15. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L, Zhou H, Xu H, Sun X, Chen X, Fan P, Cai X, Wang Q.
    Osteoporos Int; 2024 Jun 01; 35(6):997-1005. PubMed ID: 38277031
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul 01; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 17. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Wilson N, Walker S, Hartigan C, Khan N, Page M, Robinson ME, Saleh DS, Smit K, Rauch F, Siminoski K, Ward LM.
    J Clin Endocrinol Metab; 2024 Jan 18; 109(2):536-548. PubMed ID: 37610420
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB, Dai Y, Hu J, Zhao DC, Wang O, Jiang Y, Xia WB, Xing XP, Li M.
    Endocr Pract; 2020 Dec 18; 26(12):1477-1485. PubMed ID: 33471740
    [Abstract] [Full Text] [Related]

  • 20. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.
    Osteoporos Int; 2012 Aug 18; 23(8):2141-50. PubMed ID: 22159672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.